Memo Therapeutics Company
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.
MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Investors
Connections
Employee Number:
11-50
Headquarters:
Schlieren, Zurich, Switzerland, Europe
Founded Date:
2012-01-01
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 44-515-91-40
Investors:
Kurma Partners, Schroders Capital, Verve Ventures, Ysios Capital, redalpine
Ipo Status:
private
City:
Schlieren
Region:
Zurich
Country:
Switzerland
Founders:
Christoph Esslinger